Disease: Glioblastoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 GeneticVariation disease BEFREE Haplotype-specific expression of the human PDGFRA gene correlates with the risk of glioblastomas. 18464291 2008
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 GeneticVariation disease LHGDN Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. 16186508 2005
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 GeneticVariation disease BEFREE In glioblastomas (n = 45), amplification of EGFR [18 (40%)], PDGFRA [3 (7%)], KIT [2 (4%)], MET [1 (2%)], and AKT1 [1 (2%)] was detected. 31000415 2019
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 GeneticVariation disease BEFREE Tumor types were characterized by specific broad and focal chromosomal events including focal loss of the INK4A/B locus in glioblastoma and loss of the RB1 gene and amplification of the PDGFRA gene in oligodendrogliomas. 27251041 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Genomic mapping has driven the classification of glioblastoma into distinct molecular subclasses, but mechanisms that regulate tumor subclass phenotypes are only now emerging.In this issue of Cancer Cell, Lu et al. describe a phenotypic switch from PDGFRA-enriched "proneural" to EGFR-enriched "classical" features in glioblastoma upon ablation of Olig2. 27165737 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Through double-immunohistochemical staining for platelet-derived growth factor receptor α (PDGFRα) and glial fibrillary acidic protein (GFAP), this study explored the intercase variability among 45 human GBM samples regarding density of GFAP+ peritumoral astrocytes and a subset of GFAP+ peritumoral astrocyte-like cells also expressing PDGFRα. 31769546 2020
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE A younger age at diagnosis and better clinical outcome in glioblastoma patients is only seen when PDGFRA and KIT are co-amplified. 23990986 2013
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Furthermore, forced expression of miR-129-2 repressed the expression of major oncogenic genes such as PDGFRa and Foxp1 in GBMs. 26320507 2015
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE We showed that machine-based classification of GBMs with high oligodendroglioma component uncovered a set of tumors with strong associations with PDGFRA amplification, proneural transcriptional class, and expression of the oligodendrocyte signature genes MBP, HOXD1, PLP1, MOBP and PDGFRA. 24236209 2013
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. 30082792 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Although it is known that oncogenic signaling caused by overexpression of genes such as PDGFRA is responsible for robust glioma growth and cell infiltration, the mechanisms underlying glioblastoma malignancy remain largely elusive. 22080864 2011
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE KIT was amplified in 47% and VEGFR2 in 39% of the glioblastomas, respectively, and PDGFRA in 29%. 16021678 2005
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE A common theme in glioblastoma is the amplification of genes that code for growth factor receptors of the protein-tyrosine kinase family (epidermal growth factor receptor, platelet-derived growth factor receptor-alpha, met). 7654823 1995
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Labeling of PDGFRα in glioblastoma cells and tumor-associated stromal cells was highly variable, with no correlation with PFS. 27844311 2017
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE The extrachromosomal nature of ALEMs explains the observed drastic changes in the amounts of mutated oncogenes (like EGFR or PDGFRA) in glioblastoma in response to environmental changes. 25471132 2014
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Surprisingly, we observed the induction of anti-apoptotic proteins and compensatory oncogenic signals such as EDN1, EDNRB, PRKCB1, PDGF-C and PDGF-D. To conclude, we hypothesize that the newly discovered PDGFRα/Stat3/Rb1 regulatory axis might represent a potential therapeutic target for GBM treatment. 27344175 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Overexpression of PDGF system components, particularly the alpha subtype receptor (PDGFRA), is common in glial tumors, and PDGFRA gene amplification has been reported in glioblastomas. 10850862 2000
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Further analysis, including whole exome sequencing, revealed missense mutations or complex gene fusion events in PDGFRA with augmented expression in the secondary glioblastomas after radiotherapy, implicating PDGFRA as a putative driver in the development of secondary glioblastomas after treatment exposure. 29644394 2018
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. 22323597 2012
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE No significant difference was observed in the frequency of amplification of these genes in primary and secondary glioblastomas or in glioblastomas with and without IDH1 mutations, suggesting that amplification of PDGFRA, KIT and KDR may be implicated in the pathogenesis of a small fraction of both subtypes of glioblastoma. 21382095 2011
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE PDGFRA amplification was more common in cases with GBM than with PNET morphology (36 vs. 5 %, respectively), while CCND2 amplifications showed the opposite trend (5 vs. 27 %). 26482474 2016
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Glioblastomas with a proneural expression signature are characterized by frequent IDH1 mutations (i.e. genetic hallmarks of secondary glioblastomas) and PDGFRA (platelet-derived growth factor receptor-α) amplification. 23242283 2013
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE Taken together, this study identifies Dyn2 as an effector that mediates PDGFRα-SHP-2-induced glioma tumor growth and invasion, suggesting that targeting the PDGFRα-SHP-2-Dyn2 pathway may be beneficial to patients with malignant glioblastomas. 21996738 2012
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE We find evidence of regional mutational heterogeneity in multiple tumors, including mutations in TP53 and RB1 in an anaplastic oligodendroglioma and amplifications in PDGFRA and KIT in two glioblastomas (GBMs). 25608559 2014
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.400 Biomarker disease BEFREE The PDGFRA(Δ8, 9) mutant was common, being present in 40% of the glioblastoma multiformes (GBMs) with PDGFRA amplification. 20889717 2010